Emerging drugs for T-cell lymphoma

Bibliography

• The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-18
   PubMed Web of Science ®Google Scholar
• Howlander N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. 2010. Available from: http://seer.cancer.gov/csr/1975_2010/ [Cited August 2013]
   Google Scholar
• UK CR. Non-Hodgkin lymphoma incidence statistics. 2013. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/nhl/incidence/uk-nonhodgkin-lymphoma-incidence-statistics [Cited August 2013]
   Google Scholar
• Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood 2009;114:4337-53
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30
   PubMed Web of Science ®Google Scholar
• Durkop H, Latza U, Hummel M, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992;68:421-7
   PubMed Web of Science ®Google Scholar
• Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982;299:65-7
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition. WHO Press, Lyon, France; 2008
   Google Scholar
• Thompson PA, Prince HM. Breast implant-associated anaplastic large cell lymphoma: a systematic review of the literature and mini-meta analysis. Curr Hematol Malig Rep 2013;8:196-210
   PubMed Web of Science ®Google Scholar
• Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-504
   PubMed Web of Science ®Google Scholar
• Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991;79:428-37
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996;20:103-11
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998;92:76-82
   PubMed Web of Science ®Google Scholar
• Sonnen R, Schmidt W-P, Muller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005;129:366-72
   PubMed Web of Science ®Google Scholar
• Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116:3418-25
   PubMed Web of Science ®Google Scholar
• Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999;93:2697-706
   PubMed Web of Science ®Google Scholar
• Rodriguez J. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003;14:1768-75
   PubMed Web of Science ®Google Scholar
• d'Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012;30:3093-9
   PubMed Web of Science ®Google Scholar
• Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-Cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2008;27:106-13
   PubMed Web of Science ®Google Scholar
• Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20:1533-8
   PubMed Web of Science ®Google Scholar
• Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005;103:2091-8
   PubMed Web of Science ®Google Scholar
• Yim KL, Ashley S. Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma. Med Oncol 2012;29:3535-9
   PubMed Web of Science ®Google Scholar
• Ng M, Waters J, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005;92:1352-7
   PubMed Web of Science ®Google Scholar
• Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24:181-9
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: consortium for Improving Survival of Lymphoma study. J Clin Oncol 2009;27:6027-32
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009;27:5594-600
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011;29:4410-16
   PubMed Web of Science ®Google Scholar
• Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007;25:5458-64
   PubMed Web of Science ®Google Scholar
• Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 2010;28:4177-83
   PubMed Web of Science ®Google Scholar
• Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009;27:453-9
   PubMed Web of Science ®Google Scholar
• Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-Cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 2013;31(16):1970-6
   PubMed Web of Science ®Google Scholar
• Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood 2011;117:6756-67
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010;21:860-3
   PubMed Web of Science ®Google Scholar
• Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 2010;28(Suppl 1):S3-20
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84
   PubMed Web of Science ®Google Scholar
• Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007;16:1111-20
   PubMed Web of Science ®Google Scholar
• Khot A, Dickinson M, Prince HM. Romidepsin for peripheral T-cell lymphoma. Expert Rev Hematol 2013;6:351-9
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30:631-6
   PubMed Web of Science ®Google Scholar
• Pohlman B, Advani R, Duvic M, et al. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. ASH Annu Meeting Abstr 2009;114:920
   Google Scholar
• O'Connor OA, Masszi T, Savage KJ, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trial. ASCO Meeting Abstr 2013;31:8507
   Google Scholar
• Dickinson M, Cheah C, Prince H. Current epigenetic therapy for T-cell lymphoma. In: Foss F, editor. T-cell lymphoma. Humana Press, New York; 2013
   Google Scholar
• Khot A, Dickinson M, Prince HM. Panobinostat in lymphoid and myeloid malignancies. Expert Opin Investig Drugs 2013;22(9):1211-23
   PubMed Web of Science ®Google Scholar
• Zain JM, Marchi E. Pralatrexate - from bench to bedside. Drugs Today (Barc) 2010;46:91-9
   PubMed Web of Science ®Google Scholar
• Zain J, O'Connor O. Pralatrexate: basic understanding and clinical development. Expert Opin Pharmacother 2010;11:1705-14
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Hamlin PA, Portlock C, et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007;139:425-8
   PubMed Web of Science ®Google Scholar
• Izbicka E, Diaz A, Streeper R, et al. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother Pharmacol 2009;64:993-9
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009;27:4357-64
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182-9
   PubMed Web of Science ®Google Scholar
• Goy A, Pro B, Savage KJ, et al. Pralatrexate is effective in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with prior ifosfamide, carboplatin, and etoposide (ICE)-based regimens. ASH Annu Meeting Abstr 2010;116:1753
   Google Scholar
• Shustov A, Pro B, Gisselbrecht C, et al. Pralatrexate is effective as second-line treatment following cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) failure in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). ASH Annu Meeting Abstr 2010;116:4882
   Google Scholar
• Koch E, Story SK, Geskin LJ. Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy. Leuk Lymphoma 2013;54(11):2448-51
   PubMed Web of Science ®Google Scholar
• Malik SM, Liu K, Qiang X, et al. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2010;16:4921-7
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012;119:4115-22
   PubMed Web of Science ®Google Scholar
• Thompson CA. FDA approves pralatrexate for treatment of rare lymphoma. Am J Health Sys Pharm 2009;66:1890
   PubMed Web of Science ®Google Scholar
• Deng C, Pan B, O'Connor OA. Brentuximab vedotin. Clin Cancer Res 2013;19:22-7
   PubMed Web of Science ®Google Scholar
• Newland AM, Li JX, Wasco LE, et al. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate. Pharmacotherapy 2013;33:93-104
   PubMed Web of Science ®Google Scholar
• de Claro RA, McGinn K, Kwitkowski V, et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012;18:5845-9
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30(18):2190-6
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30(18):2183-9
   PubMed Web of Science ®Google Scholar
• Duvic M, Tetzlaff M, Clos AL, et al. Results of a phase II trial of brentuximab vedotin (SGN-35) for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders. ASH Annu Meeting Abstr 2012;120:3688
   Google Scholar
• Fanale MA, Shustov AR, Forero-Torres A, et al. Brentuximab vedotin administered concurrently with multi-agent chemotherapy as frontline treatment of ALCL and other CD30-positive mature T-cell and NK-cell lymphomas. ASH Annual Meeting Abstracts 2012;120:60
   Google Scholar
• Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011;17:2081-6
   PubMed Web of Science ®Google Scholar
• Ordemann R, Stöhlmacher J, Beuthien-Baumann B, et al. Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. Ann Hematol 2013;92:125-7
   PubMed Web of Science ®Google Scholar
• Mosse YP, Balis FM, Lim MS, et al. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: a Children's Oncology Group phase I consortium study. ASCO Meeting Abstr 2012;30:9500
   Google Scholar
• Pogliani EM, Dilda I, Villa F, et al. High response rate to crizotinib in advanced, chemoresistant ALK+ lymphoma patients. ASCO Meeting Abstr 2011;29:e18507
   Google Scholar
• Gambacorti Passerini C, Farina F, Stasia A, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst 2014;106:djt378
   PubMedGoogle Scholar
• Horibe K, Braiteh F, Huang H-Q, et al. Safety and clinical activity of crizotinib in patients with ALK-rearranged hematologic malignancies. Blood 2013;122:4342
   Google Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22-32
   PubMed Web of Science ®Google Scholar
• Chan AC, Neeson P, Leeansyah E, et al. Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. Leukemia 2010;24(3):592-600
   PubMed Web of Science ®Google Scholar
• Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36
   PubMed Web of Science ®Google Scholar
• Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013;27(9):1902-9
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Derenzini E, et al. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. Hematol Oncol 2013;31(4):223-4
   PubMed Web of Science ®Google Scholar
• Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012;13:716-23
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2013;31:584-91
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009;15:355-60
   PubMed Web of Science ®Google Scholar
• Dueck G, Chua N, Prasad A, et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010;116(19):4541-8
   PubMed Web of Science ®Google Scholar
• Toumishey E, Prasad A, Dueck GS, et al. Final report of a phase II clinical trial of lenalidomide monotherapy for T-cell lymphoma. Blood 2013;122:4376
   Google Scholar
• Zinzani PL, Pellegrini C, Broccoli A, et al. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma 2011;52:1585-8
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Abramson JS, Pinkus GS, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12:7174-9
   PubMed Web of Science ®Google Scholar
• Dearden CE, Khot A, Else M, et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood 2011;118:5799-802
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920-4
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Alinari L, Tani M, et al. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 2005;90:702-3
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol 2011;22:1595-600
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007;60:129-34
   PubMed Web of Science ®Google Scholar
• Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001;98:1721-6
   PubMed Web of Science ®Google Scholar
• Tobinai K, Takahashi T, Akinaga S. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Curr Hematol Malig Rep 2012;7:235-40
   PubMed Web of Science ®Google Scholar
• Jones D, O'Hara C, Kraus MD, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 2000;96:685-90
   PubMed Web of Science ®Google Scholar
• Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res 2004;10:7529-39
   PubMed Web of Science ®Google Scholar
• Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012;30:837-42
   PubMed Web of Science ®Google Scholar
• Jo T, Ishida T, Takemoto S, et al. Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult T-cell leukemia-lymphoma (ATL). ASCO Meeting Abstr 2013;31:8506
   Google Scholar
• Ishida T, Ogura M, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CCR4 antibody, in patients with relapsed peripheral and cutaneous T-cell lymphoma. ASH Annu Meeting Abstr 2012;120:795
   Google Scholar
• Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-Label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 2013;31(1):104-10
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Mahadevan D, Cebula E, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 2014;32:44-50
   PubMed Web of Science ®Google Scholar
• Cosenza M, Civallero M, Fiorcari S, et al. Romidepsin and lenalidomide show a synergistic effect in T–cell lymphoma cell lines. Blood 2013;122:5148
   Google Scholar
• Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011;117:5827-34
   PubMed Web of Science ®Google Scholar
• Lansigan F, Seropian S, Barbarotta L, Foss FM. A pilot study of sorafenib in refractory or relapsed T-cell lymphoma patients. Blood 2013;122:4356
   Google Scholar
• d'Amore F, Radford J, Relander T, et al. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol 2010;150:565-73
   PubMed Web of Science ®Google Scholar